Akura Medical has closed a $35 million series B financing that it plans to leverage to apply for FDA 510(k) clearance for its mechanical thrombectomy platform to remove blood clots.

Leading the funding round were The Capital Partnership and Cormorant Asset Management, with participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shifamed angel investors.

While there are multiple mechanical thrombectomy devices on the market, Akura’s platform is intended to be easier to use, with a smaller bore, for the removal of both soft and hard clots, the company said.